Cargando…

A toxicity-dependent feasibility bound for the escalation with overdose control approach in phase I cancer trials

Detalles Bibliográficos
Autores principales:	Wheeler, Graham, Sweeting, Michael, Mander, Adrian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660097/ http://dx.doi.org/10.1186/1745-6215-16-S2-P233

Ejemplares similares

Toxicity‐dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials
por: Wheeler, Graham M., et al.
Publicado: (2017)

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
por: Wheeler, Graham M.
Publicado: (2016)

Escalation strategies for combination therapy Phase I trials
por: Sweeting, Michael J, et al.
Publicado: (2012)

A novel Bayesian method for dual-agent Phase I dose-escalation studies using penalized D-optimality
por: Wheeler, Graham
Publicado: (2013)

A product of independent beta probabilities dose escalation design for dual-agent phase I trials
por: Mander, Adrian P, et al.
Publicado: (2015)

Escalation with Overdose Control Using Time to Toxicity for Cancer Phase I Clinical Trials
por: Tighiouart, Mourad, et al.
Publicado: (2014)

Modelling semi‐attributable toxicity in dual‐agent phase I trials with non‐concurrent drug administration
por: Wheeler, Graham M., et al.
Publicado: (2016)

AplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical Trials
por: Wheeler, Graham M., et al.
Publicado: (2016)

The transfer of genetically engineered lymphocytes in melanoma patients: a Phase I dose escalation study
por: Regan, Courtney, et al.
Publicado: (2015)

Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses
por: Heery, Christopher R, et al.
Publicado: (2015)

Antibiotic costs in bacteremic and nonbacteremic patients treated with the de-escalation approach
por: Evodia, E, et al.
Publicado: (2008)

Preliminary results of a triple peptide escalating dose vaccination phase I/II clinical trial as consolidation treatment in women affected by ovarian cancer
por: Napoletano, Chiara, et al.
Publicado: (2013)

Treatment of calcium channel blocker overdose with levosimendan
por: Sencan, A, et al.
Publicado: (2011)

Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer
por: Nemunaitis, John, et al.
Publicado: (2013)

The 3+3 versus model-based approach: implementation in the CAPCISUM pancreatic cancer trial
por: Qian, Wendi, et al.
Publicado: (2015)

Acute drug overdose in an ICU: 15 years experience
por: Cachafeiro, L, et al.
Publicado: (2010)

Radiation overdose: the utility of ct scanning in self poisoning
por: Sondh, G, et al.
Publicado: (2015)

S100B protein in heroin overdose: a pilot study
por: Brvar, M, et al.
Publicado: (2005)

PK/PD modeling supports the dose-escalation decision in VIKING
por: Lovern, M, et al.
Publicado: (2010)

De-escalation practice pattern in an Indian intensive care unit
por: Bhakta, A, et al.
Publicado: (2010)

The effectiveness of octreotide at different doses for sulfonylurea-induced hypoglycemia following overdose
por: Gul, M, et al.
Publicado: (2007)

Safety, feasibility and functionality of activated autologous dendritic cells for intratumoral injection in solid tumors: a Phase I clinical trial
por: Subbiah, Vivek, et al.
Publicado: (2015)

Addressing the barriers to implementing model based designs in dose escalation studies
por: Cornelius, Victoria, et al.
Publicado: (2015)

Some small sample properties of the EWOC design in dose escalation trials
por: Kinnersley, Nelson
Publicado: (2015)

De-escalation of empiric antibiotic therapy in sepsis - an indian observational study
por: Jakkinaboina, S, et al.
Publicado: (2015)

A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer
por: Urba, Walter, et al.
Publicado: (2015)

Dose escalations in phase I studies: Feasibility of interpreting blinded pharmacodynamic data
por: Hassing, Gerardus J., et al.
Publicado: (2022)

The Integrated Web Portal for Escalation with Overdose Control (EWOC)
por: Wang, Haibin, et al.
Publicado: (2013)

Stepped-wedge cluster randomised trials: where, when and why?
por: Grayling, Michael, et al.
Publicado: (2015)

Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial
por: Micallef, Sandrine, et al.
Publicado: (2022)

Practical implementation of an adaptive phase I/II design in chronic myeloid leukaemia: evaluating both efficacy and toxicity using the EffTox design
por: Khan, Josephine, et al.
Publicado: (2013)

A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART(®)) protein in patients with relapsed/refractory metastatic colorectal carcinoma
por: Hurwitz, Herbert, et al.
Publicado: (2014)

A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer
por: Baughman, Jan, et al.
Publicado: (2015)

De-escalation of antimicrobial therapy in Gram-negative sepsis: easier said than done?
por: Phee, L, et al.
Publicado: (2011)

De-escalation therapy: 1-year experience in a general intensive care unit
por: Gyurov, E, et al.
Publicado: (2005)

Forecasting escalation of cardio-respiratory instability using noninvasive vital sign monitoring data
por: Guillame-Bert, M, et al.
Publicado: (2015)

Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results
por: Kefford, Richard, et al.
Publicado: (2014)

Model selection and sample size adaptation: HYPAZ trial
por: Bond, Simon, et al.
Publicado: (2011)

Incorporating historical control data into the design and analysis of clinical trials
por: Bennett, Maxine, et al.
Publicado: (2015)

Triage after drug overdose: effect of the Introduction of a medical psychiatry unit on the allocation of ICU beds
por: Kleinloog, D, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_o70ia970kfcuhvmv57jtu276ea